Home › Liquid Biopsy Startup Freenome Using Recently Raised Funds to Show Clinical Validity, Utility

Liquid Biopsy Startup Freenome Using Recently Raised Funds to Show Clinical Validity, Utility

Mar 30, 2017
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Freenome is using the $65 million it recently raised through a financing round to conduct the clinical validation and utility studies that will be critical for its non-invasive, cancer screening technology to be reimbursed and meet regulatory requirements. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
20
Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27
Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Featured Webinar

Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling

Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

What's Popular?

In Cancer

  1. FDA Approves Agilent Complementary Dx for Two Additional Indications

  2. Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test

  3. OncoDNA Gains UK Reimbursement for OncoStrat&Go

  4. Shuwen Biotech Gets CE-IVD Mark for EGFR Mutation Kit

  5. HalioDx Aims to Add Breast, Lung Cancer Panels to Dx Menu Amid New Research Collaborations

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.